Project Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
177Lu-PSMA-617 abiraterone abiraterone acetate ADC ADT AI ai in healthcare antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA BRCA2 cancer immunotherapy CAR-T clinical trial crispr darolutamide docetaxel drug repurposing drug resistance enzalutamide HRR immunotherapy mcrpc metastatic hormone-sensitive prostate cancer mHSPC mRNA NEPC neuroendocrine prostate cancer olaparib oncolytic virus PARP1 PARP inhibitor Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data T-cell therapy
Latest Posts
- Darolutamide Linked to Better Real‑World Outcomes than Enzalutamide or Apalutamide in nmCRPC March 18, 2026
- AI CellVoyager Agent Turns Single‑Cell RNA‑seq Data into Continuous Hypothesis Generation March 18, 2026
- Ferroptosis-Nanoparticles Turn Prostate Tumors Hot: Docetaxel + Light Wakes Immunity March 18, 2026
- SonoPIN: Ultrasound‑Guided Microbubbles Deliver Large Cancer Drugs with Pinpoint Precision March 18, 2026
Phase 1 trial results of KPG-121
/in Clinical Trial, Metastatic, Phase 1/by MaxPT217 Receives Second FDA Fast Track Designation for Neuroendocrine Prostate Cancer Treatment
/in Clinical Trial, Metastatic, Phase 1/by MaxRecent Advances in Tumor Reversion Research
/in Preclinical Research/by MaxEmerging Radiopharmaceuticals for Low PSMA-Expressing Prostate Cancer: 67Cu-SAR-bisFAP and 67Cu-SAR-bombesin
/in Clinical Trial, Metastatic, Phase 1/by MaxPhase 1 Trial: Simple Dietary Supplement Could Supercharge Cancer-Fighting Immune Cells
/in Clinical Trial, Not PCa related/by MaxWhere Are We With Ferroptosis?
/in Observational, Post-hoc, Retrospective studies/by MaxPhase 1 Trial Recruiting: Bispecific Antibodies JNJ-87189401 and JNJ-78278343
/in Clinical Trial, Metastatic, Phase 1/by MaxTargeting LIG1 with PARP Inhibitors: E New Target Identified Using CRISPR
/in CRISPR, PARPi, Preclinical Research/by Max